Autism Access Link for Early Referral and Treatment (Autism ALERT)

March 18, 2025 updated by: Katharine Zuckerman, MD MPH, Oregon Health and Science University
Autism Access Link for Early Referral and Treatment [ALERT], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process. We hypothesize that Autism ALERT will have strong acceptability and high rates of use among primary care providers as well as among diverse low-income patients of children at risk for ASD, and that we will see higher rates of child ASD educational evaluations within six months, and shorter time between referral and ASD treatment, compared with our control.

Study Overview

Status

Completed

Detailed Description

Though significant research effort has focused on autism spectrum disorder (ASD) screening, less attention has been devoted to optimizing follow-up of children who are subsequently identified as at-risk. Despite increases in ASD screening rates, many children with ASD wait years between when autism is suspected in the primary care setting and when definitive diagnosis and treatment begin. Delayed and missed diagnoses are particularly problematic for low-income and racial/ethnic minority children in the US, who experience higher rates of these adverse outcomes. In this project, we propose to pilot test Autism Access Link to Early Referral and Treatment (Autism ALERT), a statewide monitoring and case management program to accelerate access to ASD diagnosis and treatment among children with suspected ASD the primary care setting. The system will reduce the time between identification of suspected ASD in the primary care setting and establishment of ASD diagnosis and treatment services, by reducing family barriers to care, decreasing primary care provider burdens, and simplifying referral processes. The program will be available to any Oregon child age 12-54 months, regardless of health system or payor type. Autism ALERT will become part of the Help Me Grow national network, which gives it potential for statewide and national spread. In this proposed research, we will pilot test Autism ALERT by comparing it to an existing ASD screening intervention in 6 Oregon primary care practices. Primary goals of this pilot project are to assess feasibility and acceptability of Autism ALERT for primary care providers and families, to test the mechanism of action of Autism ALERT, to pilot test efficacy in reducing time to autism diagnosis and treatment, and to test fidelity of protocol implementation. If successful, this project will be expanded into an implementation/effectiveness R01 in which the program will be tested throughout the state of Oregon. In the long term, this research will result in a sustainable, evidence-based statewide and ultimately national monitoring system children with suspected ASD.

Study Type

Interventional

Enrollment (Actual)

148

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oregon
      • Portland, Oregon, United States, 97239
        • Ohsu Cdrc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 4 years (Child)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

child's primary care provider suspects the child has ASD, child is patient at one of the study clinics, child age 12 to 54 months, family speaks English or Spanish, no prior ASD medical diagnosis or ASD diagnostic evaluation

Exclusion Criteria:

Previous diagnosis of ASD or prior diagnostic evaluation for ASD.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Screening + Autism ALERT
Clinics in the intervention arm receive Autism ALERT plus an ASD screening intervention (START Autism).
Autism Access Link for Early Referral and Treatment [ALERT], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
Autism screening intervention only.
Other Names:
  • START Autism
Active Comparator: Screening Only
Clinics in the comparison intervention (control) arm receive the ASD screening intervention only (START Autism).
Autism screening intervention only.
Other Names:
  • START Autism

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in satisfaction with Care Coordination in general and for autism in particular
Time Frame: At enrollment and study end (~9 months after enrollment)
2 separate provider survey measures
At enrollment and study end (~9 months after enrollment)
Change in Parent stress
Time Frame: At enrollment and 6 months after enrollment
Parent Survey - Parenting Stress Index
At enrollment and 6 months after enrollment
Change in Parenting stress
Time Frame: At enrollment and 6 months after enrollment
Questionnaire on Resources and stress - Short Form
At enrollment and 6 months after enrollment
Change in Family Empowerment
Time Frame: At enrollment and 6 months after enrollment
Parent Survey - Family Empowerment Scale, Family Subscale
At enrollment and 6 months after enrollment
Change in Family Centered and Coordinated Care
Time Frame: At enrollment and 6 months after enrollment
Parent Survey - Items from National Survey of Children's Health, Medical Home item set
At enrollment and 6 months after enrollment
Family Satisfaction with Program
Time Frame: 6 months after enrollment - Autism ALERT + Screening arm only
Parent Survey items - Satisfaction with Interpersonal Relationship with Navigator (PSN-I), Client Satisfaction Questionnaire - 8
6 months after enrollment - Autism ALERT + Screening arm only
% referred to program who complete an ASD educational evaluation within 6 months
Time Frame: 6 months after enrollment
Administrative data - Oregon Early Intervention/Early Childhood Special Ed (EI/ECSE) database
6 months after enrollment
Time from EI/ECSE referral to ASD treatment in EI/ECSE, among children with ASD
Time Frame: measured 9 months after enrollment
Administrative data - Oregon EI/ECSE database
measured 9 months after enrollment
Family self-reported ASD knowledge
Time Frame: At enrollment and 9 months after enrollment
5-item survey measure
At enrollment and 9 months after enrollment
Change in provider self-efficacy about autism management
Time Frame: At enrollment and at study end (~9 months after enrollment)
1-item survey measure
At enrollment and at study end (~9 months after enrollment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in provider autism paperwork burden
Time Frame: At enrollment and at study end (~9 months after enrollment)
Provider survey item
At enrollment and at study end (~9 months after enrollment)
Time from EI/ECSE referral to evaluation among children with ASD
Time Frame: measured 9 months after enrollment
Administrative data - Oregon EI/ECSE database
measured 9 months after enrollment
Age of EI/ECSE educational determination, among children with ASD
Time Frame: measured 9 months after enrollment
Administrative data - Oregon EI/ECSE database
measured 9 months after enrollment
% with ASD determination receiving ASD services 6 months after enrollment
Time Frame: measured 9 months after enrollment
Administrative data - Oregon EI/ECSE database
measured 9 months after enrollment
monthly service hours among children with ASD 6 months after enrollment
Time Frame: measured 9 months after enrollment
Administrative data - Oregon EI/ECSE database
measured 9 months after enrollment
age of ASD medical diagnosis among children on Medicaid
Time Frame: Measured 1 year after study enrollment
Administrative data - Medicaid claims
Measured 1 year after study enrollment
% with ASD medical diagnosis receiving ASD therapy 6 months after enrollment, among children on Medicaid
Time Frame: Measured 1 year after study enrollment
Administrative data - Medicaid claims
Measured 1 year after study enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Actual)

April 1, 2023

Study Completion (Actual)

January 4, 2024

Study Registration Dates

First Submitted

April 7, 2021

First Submitted That Met QC Criteria

April 22, 2021

First Posted (Actual)

April 27, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 18, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We will share data through the NIMH Data Archive as required by the grant.

IPD Sharing Time Frame

Data will be available indefinitely starting with the conclusion of the study.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism Spectrum Disorder

Clinical Trials on Autism ALERT

Subscribe